Sanofi Halts Amlitelimab, Citing High Competitive Bar Amid Emerging OX40 Pathway Safety Risks

Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis

Sanofi has announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision, part of a strategic pipeline assessment, means the drug will not be submitted for global regulatory reviews. Despite the ESTUARY phase 3 study showing long-term maintenance of clinical response, Sanofi determined that amlitelimab would not offer a meaningful improvement over the current standard of care for AD patients.

• Sanofi's decision to halt amlitelimab's development in moderate-to-severe atopic dermatitis was driven by a strategic assessment concluding that the totality of efficacy and safety evidence, while demonstrating long-term response maintenance in the ESTUARY study, did not position the drug as a significant advancement over existing treatments.
• Amlitelimab (SAR445229, KY1005) is a fully human, non-T cell depleting monoclonal antibody that targets and blocks OX40L, a crucial immune regulator. Its novel mechanism of action aims to selectively normalize T-cell-mediated inflammation during the inflammatory prequel without causing T-cell depletion.
• Despite the discontinuation for atopic dermatitis, Sanofi confirmed that its full-year 2026 financial guidance remains unchanged. Furthermore, a separate Phase 2 study evaluating amlitelimab for celiac disease is still active, with its results anticipated to be released in the second half of 2026.

Evaluating Amlitelimab's Efficacy and Safety in Atopic Dermatitis

Amlitelimab, a fully human noncytotoxic, nondepleting anti-OX40L monoclonal antibody, has consistently demonstrated an unremarkable and favorable safety profile across its clinical development program in atopic dermatitis. In the phase 2a study conducted across 19 hospitals in Germany, Poland, Spain, and the UK, 88 patients (37 women [42%], 51 men [58%]; mean age 33.6 [11.9] years) received either low-dose (200 mg) or high-dose (500 mg) intravenous amlitelimab, with three maintenance doses administered at 4, 8, and 12 weeks. Both dosing regimens were well tolerated, with no hypersensitivity events reported and safety follow-up extending to week 36. The co-primary endpoint of this trial included incidence of treatment-emergent adverse events (TEAEs) among all patients receiving at least one dose of study drug, and no serious treatment-related adverse events were identified.

This favorable tolerability profile was corroborated in the larger phase 2b STREAM-AD trial, which enrolled 390 patients in Part 1 and 190 patients in Part 2, evaluating subcutaneous amlitelimab at doses of 250 mg (with a 500-mg loading dose), 250 mg, 125 mg, or 62.5 mg every 4 weeks over a 24-week treatment period. Amlitelimab maintained a favorable safety profile through 52 weeks of follow-up, with sustained efficacy observed alongside consistent tolerability. Meta-analytic data further support these findings: the incidence of any treatment-emergent adverse event was not statistically significant compared with placebo for either the high-dose (risk ratio = 1.14; 95% CI = 0.82–1.59; P = 0.443) or low-dose groups (risk ratio = 1.10; 95% CI = 0.84–1.45; P = 0.486).

Within the broader context of OX40-OX40L pathway inhibition, amlitelimab compares favorably to rocatinlimab, with both agents shown to be safe and well tolerated in atopic dermatitis populations. This class-level acceptability aligns with the rationale behind next-generation biologic engineering, which has focused on attenuating antibody-dependent cellular cytotoxicity to further improve tolerability. Overall, published data characterize amlitelimab as generally well tolerated in the short term, though the available literature does not provide granular detail on the most common individual adverse events or serious adverse events by type or frequency, nor does it report indication-specific safety data beyond atopic dermatitis, such as in asthma or other inflammatory conditions.

The OX40L Inhibitor Landscape in Atopic Dermatitis

Amlitelimab, a fully human nondepleting monoclonal antibody targeting OX40 ligand (OX40L) on antigen-presenting cells, is one of several agents exploiting the OX40-OX40L pathway as a novel therapeutic target in moderate-to-severe atopic dermatitis (AD). Two other investigational agents—rocatinlimab and telazorlimab—share this same mechanism of action, and all three have advanced through phase II clinical evaluation for this indication. The intervention model for the amlitelimab trial, the most extensively characterized among the three, is detailed below.

Addressing Unmet Needs in Atopic Dermatitis Treatment

Despite significant advances in understanding atopic dermatitis (AD) pathogenesis and expanding the therapeutic armamentarium, substantial gaps remain across diagnosis, treatment access, adherence, and patient-reported outcomes. Evidence spanning from 2008 through 2026 reveals persistent unmet needs that span clinical, systemic, and patient-experience domains, underscoring the complexity of achieving durable disease control in real-world practice.

• Incomplete and non-durable clinical clearance: Achieving complete, long-lasting clearance remains elusive for most patients, with long-term safety and healthcare burden persisting as key unmet needs even as newer therapies enter the market (2026 evidence).

• Lack of standardization in diagnosis, response definitions, and guideline implementation: No standardized definition exists for treatment response to topical corticosteroids or for broader clinical response, contributing to heterogeneity in practice and complicating trial design. Consensus among dermatologists remains strikingly low—22.7% for diagnosis and 19.0% for treatment approaches (though 86% for long-term management)—reflecting limited real-world implementation of clinical guidelines (2022, 2026 evidence).

• Diagnostic delay and disease heterogeneity: Mean age at diagnosis is 19.4 years, with delays averaging nearly 3 years; AD's varied clinical presentations complicate timely and accurate diagnosis, particularly in primary care and atypical adult-onset cases. Prognostic criteria to predict disease duration and validated biomarkers for staging are notably lacking (2020, 2022, 2024 evidence).

• Persistent disease burden despite treatment: Between 45.9% and 73.5% of patients present with moderate-to-severe disease, and more than half continue to experience moderate-to-severe pruritus, frequent flares, and impaired quality of life—with negative downstream effects on sleep, mental health, social functioning, and work productivity (2024 evidence). Notably, even when subjective symptoms like itching and dryness improve, underlying inflammation in the deeper epidermis/dermis often persists (2015 evidence).

• Treatment-related burden and reduced quality of life: The majority of patients (63.4%) report therapy-related issues, with treatment itself accounting for 8.7% of the total reduction in health-related quality of life—highlighting that therapeutic regimens can themselves be a source of burden that must be factored into treatment planning (2018 evidence).

• Adherence barriers: Nonadherence, especially to topical therapies, remains one of the most common causes of treatment failure. Key barriers include strained patient-provider relationships, concerns about medication safety, and information deficits—pointing to a need for improved patient education and trust-building (2023 evidence).

• Historical and ongoing systemic therapy limitations: Prior to recent biologic approvals, systemic corticosteroids were the only FDA-approved systemic option despite guideline discouragement and known rebound effects, forcing reliance on off-label immunosuppressants with serious adverse effect profiles; this left a significant proportion of moderate-to-severe patients untreated. Slow guideline update cycles continue to limit timely incorporation of novel therapies into standard practice (2018 evidence).

• Disparities in access to advanced therapies: Dermatologic injectable biologics such as dupilumab are not uniformly accessible—91.5% of prescribers in 2017 practiced in metropolitan counties versus just 12 in non-metro areas, revealing geographic and Medicare-linked access disparities that may emerge as soon as novel biologics reach the market (2021 evidence).

• Gaps in patient-centered outcomes and satisfaction data: Data on patients' treatment goals and satisfaction remain sparse; disease severity explains only 20% of the variance in treatment satisfaction, suggesting that clinical metrics alone fail to capture the patient experience. Greater integration of patient education and treatment competence-building into clinical practice is needed (2008, 2022 evidence).

Sanofi's Amlitelimab Exit: Redefining AD's High Bar

Sanofi's decision to halt the clinical development of amlitelimab, an OX40-ligand monoclonal antibody for moderate-to-severe atopic dermatitis, marks a pivotal moment for the OX40 pathway and the broader AD therapeutic landscape. While phase 2 and 3 studies indicated amlitelimab's ability to deliver clinically meaningful improvements in disease severity and patient-reported outcomes, with notable durability of response even after treatment cessation, the company concluded it would not offer a 'meaningful improvement' over existing standards of care. This highlights the increasingly high bar for novel therapies in a market transformed by effective biologics.

The OX40-OX40L pathway has long been identified as a critical driver of T-cell-mediated inflammation in atopic dermatitis, making its inhibition a promising therapeutic strategy. Amlitelimab, alongside rocatinlimab (an anti-OX40 antibody), represented the forefront of this mechanism. However, the competitive intensity in AD is formidable. Dupilumab, an established biologic, consistently demonstrates reliable efficacy and boasts extensive long-term safety data, setting a high benchmark for new entrants. Other emerging agents also contribute to a crowded pipeline, demanding clear differentiation in efficacy, safety, or patient convenience.

Beyond competitive pressures, the OX40 pathway has faced recent safety scrutiny. The discontinuation of rocatinlimab following confirmed and suspected cases of Kaposi's sarcoma, coupled with two reported cases in the amlitelimab program (in patients with known risk factors), introduces a significant risk factor for the entire class. While a causal link remains unproven, the biological plausibility necessitates a re-evaluation of development strategies, patient selection, and risk mitigation for future OX40/OX40L inhibitors. This event underscores that even with promising clinical data, a complex interplay of market dynamics, competitive differentiation, and emerging safety signals can dictate a drug's ultimate fate. The future of OX40 pathway modulation in AD will likely require a more selective approach, focusing on refined molecule design and targeted patient populations to maximize benefit while carefully managing inherent risks.